Literature DB >> 34272700

Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

Jin Zhou1, Upendra A Argikar2, John O Miners3.   

Abstract

Glucuronidation, catalyzed by uridine diphosphate glucuronosyltransferases (UGTs), is an important process for the metabolism and clearance of many lipophilic chemicals, including drugs, environmental chemicals, and endogenous compounds. Glucuronidation is a bisubstrate reaction that requires the aglycone and the cofactor, UDP-GlcUA. Accumulating evidence suggests that the bisubstrate reaction follows a compulsory-order ternary mechanism. To simplify the kinetic modeling of glucuronidation reactions in vitro, UDP-GlcUA is usually added to incubations in large excess. Many factors have been shown to influence UGT activity and kinetics in vitro, and these must be accounted for during experimental design and data interpretation. While the assessment of drug-drug interactions resulting from UGT inhibition has been challenging in the past, the increasing availability of UGT enzyme-selective substrate and inhibitor "probes" provides the prospect for more reliable reaction phenotyping and assessment of drug-drug interaction potential. Although extrapolation of the in vitro intrinsic clearance of a glucuronidated drug often underpredicts in vivo clearance, careful selection of in vitro experimental conditions and inclusion of extrahepatic glucuronidation may improve the predictivity of in vitro-in vivo extrapolation. Physiologically based pharmacokinetic (PBPK) modeling has also shown to be of value for predicting PK of drugs eliminated by glucuronidation.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Albumin effect; Atypical kinetics; Bisubstrate kinetics; Drug–drug interactions; Enzyme kinetics; Glucuronidation; Human liver microsomes; In vitro–in vivo extrapolation; Latency; PBPK—physiologically based pharmacokinetic modeling; Protein–protein interactions; Reaction phenotyping; Relative activity factor; UDP-glucuronic acid; UDP-glucuronosyltransferase; β-Glucuronidase

Year:  2021        PMID: 34272700     DOI: 10.1007/978-1-0716-1554-6_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  162 in total

Review 1.  The UDP-glucuronosyltransferases as oligomeric enzymes.

Authors:  Moshe Finel; Mika Kurkela
Journal:  Curr Drug Metab       Date:  2008-01       Impact factor: 3.731

Review 2.  Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily.

Authors:  Peter I Mackenzie; Karl Walter Bock; Brian Burchell; Chantal Guillemette; Shin-ichi Ikushiro; Takashi Iyanagi; John O Miners; Ida S Owens; Daniel W Nebert
Journal:  Pharmacogenet Genomics       Date:  2005-10       Impact factor: 2.089

3.  Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases.

Authors:  Leena Luukkanen; Jyrki Taskinen; Mika Kurkela; Risto Kostiainen; Jouni Hirvonen; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2005-03-31       Impact factor: 3.922

Review 4.  Unusual glucuronides.

Authors:  Upendra A Argikar
Journal:  Drug Metab Dispos       Date:  2012-04-19       Impact factor: 3.922

Review 5.  Drug glucuronidation in humans.

Authors:  J O Miners; P I Mackenzie
Journal:  Pharmacol Ther       Date:  1991       Impact factor: 12.310

6.  Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10.

Authors:  Oranun Kerdpin; Peter I Mackenzie; Kushari Bowalgaha; Moshe Finel; John O Miners
Journal:  Drug Metab Dispos       Date:  2009-06-01       Impact factor: 3.922

Review 7.  Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches.

Authors:  John O Miners; Paul A Smith; Michael J Sorich; Ross A McKinnon; Peter I Mackenzie
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

8.  The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.

Authors:  John O Miners; Peter I Mackenzie; Kathleen M Knights
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

9.  Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites.

Authors:  Verawan Uchaipichat; Aleksandra Galetin; J Brian Houston; Peter I Mackenzie; J Andrew Williams; John O Miners
Journal:  Mol Pharmacol       Date:  2008-07-22       Impact factor: 4.436

10.  Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4.

Authors:  Takahiro Kubota; Benjamin C Lewis; David J Elliot; Peter I Mackenzie; John O Miners
Journal:  Mol Pharmacol       Date:  2007-07-17       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.